Montenegro
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.19 (0.14–0.24)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.16 (0.061–0.29) 25 (9.8–47)
Incidence  (includes HIV+TB) 0.13 (0.11–0.13) 21 (18–22)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.42 (0.37–0.44)
Case detection, all forms (%) 93 (89–110)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0 (0–5.4) 0 (0–52)
MDR-TB cases among notified pulmonary
TB cases
0 (0–6) 0 (0–5)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 67   5
Pulmonary, clinically diagnosed 36   3
Extrapulmonary 8   0
       
Total new and relapse 119    
Previously treated, excluding relapses 1    
Total cases notified 120    
Among 119 new and relapse cases:
1 (<1%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 67 (100%) 5 (56%) 72
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 98 (82)
HIV-positive TB patients 2 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 2 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 84
Previously treated cases, excluding relapse, registered in 2012  
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 0
XDR-TB cases started on second-line treatment in 2011 0
Laboratories 2013  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 8.0
Drug susceptibility testing (per 5 million population) 8.0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 31%
% Funded internationally 8%
% Unfunded 62%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-06 Data: www.who.int/tb/data